Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

2020 State Legislative Roundup: The Year That Could Have Been & the Year That Was

Joseph Cantrell, JD  |  August 21, 2020

“The Year That Could Have Been” might be an apt title for any retrospective piece about 2020, but especially so regarding legislative affairs. Typically, years of work go into laying the foundation for policy change. Despite the focus on final votes, much of the work is done far in advance of those headline-grabbing roll calls. Days and nights spent away from families to build coalitions; in untold numbers of meetings with partners, legislators and the opposition;  and on phone calls—these countless hours of behind-the-scenes work are needed to move toward the single inflection point of pass or fail. That slow build is what makes 2020 so frustrating from a legislative perspective.

Interrupted Sessions & Shifting Agendas
Going into the year, we were anticipating movement in states on many key issues, such as utilization management reform and pharmacy benefit manager (PBM) regulations. One hundred fifty-eight bills relating to PBM regulations, 61 on drug supply chain pricing transparency and 69 relating to coupons and cost sharing had been filed. The groundwork had been laid for 2020 to be a very important year for state legislative activity.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, those expectations were dashed as legislators shifted their focus to gaping budget holes, policy problems surrounding COVID-19, emergency licensing for healthcare providers and myriad other emergency items that no one anticipated late last year. Almost no area of life has been left untouched by COVID-19, and state legislative sessions were no exception.

Forty-two states experienced an interruption or delay in the legislative session stemming from concerns over the virus, and agendas shifted dramatically. Of the 69 coupon and cost sharing bills introduced, eight have been signed into law. Five of those only apply to insulin prescriptions. Of the 158 bills seeking new regulations on PBMs, only 19 have passed, with Georgia being the only state to pass something resembling the sweeping reform that was not uncommon only a year ago. And of the 61 transparency bills, only two have crossed the legislative finish line.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There has been one bright spot of legislative activity. We were expecting to see as many as five states pass utilization management reform; to date three—Louisiana, North Carolina and South Dakota—have passed significant step therapy reform bills. We are still working to get step therapy reform passed in Massachusetts. We remain hopeful, although a victory is far from certain.

Outside step therapy, the remaining statistics reflect part of the extensive toll of COVID-19. The work, the energy and momentum to move pieces of legislation vanished in light of the health emergency, seemingly in an instant. Like many healthcare facilities, our legislatures were overwhelmed and consumed by the response to the pandemic.

Page: 1 2 | Single Page
Share: 

Filed under:Legislation & Advocacy Tagged with:AdvocacyLegislationPharmacy benefit manager reformstate legislationstep therapy legislation

Related Articles

    What to Expect in Healthcare Policy from the 2023 State Legislative Sessions

    February 21, 2023

    With 2023 state legislative sessions underway, early prevailing themes may forecast areas where we will see gains this year. Key issues include utilization management, copay accumulator bans, white bagging and pharmacy benefit manager reform.

    Slow but Steady: 2023 State Legislative Progress

    May 23, 2023

    This legislative season has seen key pharmacy benefit manager reforms but slow movement on other issues, such as copay accumulators and utilization management. The ACR is also monitoring emerging topics, such as biomarker testing and post-public health emergency telehealth reforms.

    Early Activity Holds Signs of Hope for 2019 State Legislative Cycle

    February 25, 2019

    The 2019–2020 legislative cycle in the states holds real hope and opportunity for critical reforms to protect rheumatology practices and patients. It is important to note that because of the state legislative process, bill passage almost always comes later in the legislative session. Although the rheumatology community has not yet seen many official wins, early…

    The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

    November 23, 2021

    New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences